Bernstein Liebhard LLP’s Post

Avista Healthcare Partners VI Closes On $1.5 Billion📰 Avista Capital Partners has closed its 6th fund at $1.5bn, exceeding their $1.25bn. This fund aims to continue their successful strategy of value creation and growth in products and technology healthcare businesses. Fund 6 is their 3rd dedicated healthcare fund and will be invested across a number of sub-sectors including outsourced pharma, medical devices, and healthcare technology. • Avista Capital Partners has closed its 6th fund at $1.5bn, exceeding their $1.25bn. • This fund aims to continue their successful strategy of value creation and growth in products and technology healthcare businesses. • Fund 6 is their 3rd dedicated healthcare fund and will be invested across a number of sub-sectors including outsourced pharma, medical devices, and healthcare technology. https://lnkd.in/eB-zAxNE #privateequitynews #privatequity #rawselection

PitchBook published an analysis of McGuireWoods LLP’s 20th Healthcare Private Equity and Finance Conference, providing insights on the state of #healthcare deal activity, the future of physician practice management investing and opportunities in pharma services. https://lnkd.in/ghaVP_AV #HCPE2024 #healthcareprivateequity #privateequity

🌟💬 Xtalks Spotlight: In this exclusive interview with Alison O'Neill, Chief Operating Officer at YPrime, to explore the power of collaboration in clinical trials. With over 35 years of experience in patient-centric trials, Alison shares how a partnership mindset can drive significant value for sponsors, leading to smoother project deliveries and better patient outcomes. ⏩ Watch + read the Spotlight with Alison O'Neill here: https://buff.ly/4dOa9cj #ClinicalTrials #Compliance #ClinicalResearch #ClinicalOperations #ClinicalDevelopment #QualityManagement #QualityCompliance #XtalksSpotlight

Some things just never change - here we go again #healthcare, one step forward two steps back. Pitchbook's PE activity for 2023 report highlights growing aversion and heightened risk of investments in #mentalhealth , #homebasedcare (very loaded topic there) and #skillednursingfacility . Interesting to see investment in dental and vision services decline - these are great points of engaging patients for prevention... At the same time, deal growth within the usual financial staples of cardio, imaging and... it looks like investment in hospital and health systems? Investment in Primary Care seems to be up - who would argue with the leverage of Medicare Advantage by the likes of VillageMD, Agilon, etc. Looks like the hype of value following the strain of COVID has cooled and it is back to business as usual. I was taught from my first day in healthcare work, its 'follow the dollar' - no change there. Let's follow the patient.

🌟💬 Xtalks Spotlight: In this exclusive interview with Alison O'Neill, Chief Operating Officer at YPrime, to explore the power of collaboration in clinical trials. With over 35 years of experience in patient-centric trials, Alison shares how a partnership mindset can drive significant value for sponsors, leading to smoother project deliveries and better patient outcomes. ⏩ Watch + read the Spotlight with Alison O’Neill here: https://buff.ly/4dOa9cj #ClinicalTrials #Compliance #ClinicalResearch #ClinicalOperations #ClinicalDevelopment #QualityManagement #QualityCompliance #XtalksSpotlight

“The more transparent the communication is, the easier it is to run a clinical trial and therefore benefit the clinical trial process.” Take a listen to what Alison O'Neill, YPrime’s Chief Operating Officer, has to say about the importance of a quality and operations partnership in this Xtalks interview: #clinicaltrialquality, #clinicaltrialcommunication, #YPrime

Q2 2024 HEALTHCARE M&A QUARTERLY UPDATE: The healthcare deal environment is currently sluggish, with private equity funds holding out for fully market-ready targets despite having ample capital. This cautious approach has kept deal-making subdued, but momentum is building for a more dynamic environment in 2025. See more trends, discover head and tailwinds in the oncology and physician practice management verticals, recent healthcare transactions, and more in our latest update, https://bit.ly/4doheAM #Healthcare #MandA

Fortis Healthcare Secures CCI Approval for Agilus Diagnostics Stake Acquisition https://lnkd.in/g75ZbZta #FortisHealthcare #AgilusDiagnostics #HealthcareAcquisition #CCIApproval #HealthcareIndustry Fortis Healthcare has received CCI approval to acquire an additional 31.52% stake in Agilus Diagnostics, increasing its ownership to 89.2%. This strategic move aims to enhance integrated healthcare services, improve diagnostic capabilities, and ultimately benefit patient care. Explore the details and implications of this significant acquisition in the healthcare landscape.

Industry leaders are coming together to explore the future of Patient Access Organizations (aka Clinical Trial Site Organizations). Paul Evans (CEO, Velocity Clinical Research, Inc.), Lori Wright (CEO, Evolution Research Group), Carlos Orantes (CEO, Alcanza Clinical Research), Aidrian Otte (Operating Partner, LongueVue Capital) and Jennifer Byrne (CEO, Javara) share their insights on the challenges and opportunities facing clinical trials today. From patient recruitment to navigating complex regulations, these experts discuss how PAOs are driving innovation and transforming the clinical research landscape. Watch the full panel discussion for a deeper dive into the future of clinical trials with perspectives from those shaping the industry. https://hubs.li/Q02R8VwC0 #InvestmentBanking #MergersandAcquisitions #ClinicalResearch #PatientAccessOrganizations #HealthcareInnovation

New Post: Avista Healthcare Partners on the specialist dividend in healthcare - This article, sponsored by Avista Healthcare Partners, discusses the shift from "generalist" to "specialist" approaches in healthcare private equity, emphasizing the need for deep sector expertise to ensure successful investments. David Burgstahler, CEO of Avista, highlights the firm's nearly 30-year history in healthcare, focusing on mid-market product and technology investments, leading to sustainable growth. Avista's strategy involves collaboration with seasoned operating partners and maintaining a narrow focus on six subsectors. The firm prioritizes regulatory compliance and transparency, fostering relationships with regulators to navigate challenges, ultimately achieving significant financial returns through its specialized approach. Read the full article here https://lnkd.in/gX4kPqex #Venturecapital #VC #investment #LP #Limited Partner